For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

UNITED THERAPEUTICS' THIRD QUARTER 2001 FINANCIAL RESULTS DEMONSTRATE CONTINUED GROWTH IN REVENUES

Silver Spring, MD, November 8, 2001: United Therapeutics Corporation (Nasdaq: UTHR) today announced financial results for the third quarter ended September 30, 2001.

"We are pleased to announce that United Therapeutics ended its third quarter in very strong financial condition," said Fred Hadeed, Chief Financial Officer. "At September 30, 2001, United Therapeutics had $181.2 million of cash and investments and practically no debt. Revenues during the quarter were $1.3 million. This was 325% higher from the same quarter one year ago."

Revenues in the third quarter of 2001 were $1.3 million as compared to revenues of $404,000 in the previous year. The increase was due primarily to sales by subsidiaries acquired late in 2000.

Research and development expenses were $8.0 million in the third quarter of 2001 as compared to $8.1 million in the third quarter of 2000. The decrease was due primarily to reduced patient enrollment in clinical trials. Sales and marketing expenses were $962,000 in the third quarter of 2001 as compared to none in the third quarter of 2000. Cost of sales were $859,000 in the third quarter of 2001 as compared to $265,000 in the third quarter of 2000. These increases were due primarily to expanded activities of subsidiaries.

Interest income was $2.2 million in the third quarter of 2001 as compared to $3.4 million in the third quarter of 2000. This decrease was attributable to reductions in market interest rates and less cash available for investing.

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious disease with unique therapeutic products.

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS DATA

	Three months ended September 30,		Nine months ended September 30,	
	2001	**2000**	**2001**	**2000**
Revenues:				
Sales	$ 1,077,053	$ 353,891	$ 3,474,774	$ 1,109,591
Sales to affiliates	185,814	-	541,200	-
Grant Revenue	52,970	50,000	96,331	150,000
Total Revenue	1,315,837	403,891	4,112,305	1,259,591
Operating Expenses:				
Research and development	8,014,410	8,135,688	26,080,312	42,848,352
General and administrative	3,378,005	2,426,571	10,373,565	7,924,105
Sales and marketing	961,737	-	2,695,626	-
Cost of sales	859,372	264,547	2,389,366	918,417
Total operating expenses	13,213,524	10,826,806	41,538,869	51,690,874
Loss from operations	(11,897,687)	(10,422,915)	(37,426,564)	(50,431,283)
Other income (expense)				
Interest income	2,185,651	3,438,644	7,923,859	6,709,370
Interest expense	(31,104)	(34,541)	(124,527)	(90,201)
Equity loss in affiliate	(106,941)	-	(261,555)	-
Other - net	39,186	4,789	28,171	76,178
Total other income (expense)	2,086,792	3,408,892	7,565,948	6,695,347
Net loss before income tax	(9,810,895)	(7,014,023)	(29,860,616)	(43,735,936)
Income tax	-	-	-	-
Net loss	$ (9,810,895)	$ (7,014,023)	$ (29,860,616)	$ (43,735,936)
Net loss per common share – basic and diluted	$ (0.48)	$ (0.35)	$ (1.47)	$ (2.32)
Weighted average number of common shares outstanding – basic and diluted	20,250,167	19,990,563	20,306,124	18,871,366

CONSOLIDATED BALANCE SHEET DATA

	September 30, 2001	**December 31, 2000**
Cash, Cash Equivalents, Marketable Investments, and Certificate of Deposit	$181,157,623	$215,990,326
Total Assets	$218,078,165	$250,644,984
Total Stockholders' Equity	$203,573,066	$234,737,782